Maxim Group Issues Negative Estimate for MediWound Earnings

Posted by George Bondi on Jun 5th, 2026

MediWound Ltd. (NASDAQ:MDWD – Free Report) – Research analysts at Maxim Group decreased their Q2 2026 earnings estimates for MediWound in a research note issued on Friday, May 29th. Maxim Group analyst M. Okunewitch now forecasts that the biopharmaceutical company will earn ($0.72) per share for the quarter, down from their previous forecast of ($0.58). The consensus estimate for MediWound’s current full-year earnings is ($2.49) per share. Maxim Group also issued estimates for MediWound’s Q3 2026 earnings at ($0.59) EPS, Q4 2026 earnings at ($0.53) EPS, FY2026 earnings at ($2.09) EPS, Q1 2027 earnings at ($0.40) EPS, Q2 2027 earnings at ($0.42) EPS, Q3 2027 earnings at ($0.42) EPS, Q4 2027 earnings at ($0.44) EPS, FY2027 earnings at ($1.68) EPS, Q1 2028 earnings at ($0.39) EPS, FY2028 earnings at ($0.98) EPS and FY2029 earnings at $0.82 EPS.

A number of other brokerages have also issued reports on MDWD. Oppenheimer restated an “outperform” rating and set a $32.00 target price (down from $33.00) on shares of MediWound in a research report on Wednesday, May 27th. Weiss Ratings restated a “sell (d-)” rating on shares of MediWound in a research report on Tuesday, April 21st. HC Wainwright restated a “buy” rating and set a $36.00 target price on shares of MediWound in a research report on Thursday, May 28th. Finally, Wall Street Zen upgraded shares of MediWound from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 30th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $34.00.

Check Out Our Latest Stock Analysis on MDWD

MediWound Price Performance

MDWD stock opened at $14.45 on Friday. The company’s 50 day simple moving average is $16.39 and its 200-day simple moving average is $17.31. The firm has a market capitalization of $185.68 million, a PE ratio of -6.39 and a beta of 0.16. MediWound has a 12 month low of $13.54 and a 12 month high of $22.09.

MediWound (NASDAQ:MDWD – Get Free Report) last released its quarterly earnings results on Wednesday, May 27th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.42. The business had revenue of $1.48 million for the quarter, compared to analyst estimates of $3.37 million. MediWound had a negative net margin of 180.30% and a negative return on equity of 67.22%. During the same period in the prior year, the business earned ($0.07) earnings per share.

Hedge Funds Weigh In On MediWound

Hedge funds have recently made changes to their positions in the stock. Quarry LP acquired a new position in shares of MediWound in the 4th quarter valued at $26,000. BNP Paribas Financial Markets boosted its holdings in shares of MediWound by 90.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 723 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of MediWound by 69.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 649 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after purchasing an additional 999 shares during the last quarter. Finally, MetLife Investment Management LLC acquired a new position in shares of MediWound in the 4th quarter valued at $109,000. Institutional investors and hedge funds own 46.83% of the company’s stock.

Insider Buying and Selling at MediWound

In related news, Director David Morton Fox purchased 3,537 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were bought at an average price of $14.11 per share, for a total transaction of $49,907.07. Following the acquisition, the director directly owned 22,283 shares in the company, valued at $314,413.13. This trade represents a 18.87% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link. 9.20% of the stock is currently owned by company insiders.

MediWound News Roundup

Here are the key news stories impacting MediWound this week:

Positive Sentiment: Craig Hallum raised its FY2026 EPS estimate for MediWound, suggesting slightly better near-term profitability than previously expected.
Positive Sentiment: Craig Hallum also increased its Q3 2026 and Q4 2027 EPS estimates, signaling some improvement in its longer-range outlook for the company.
Positive Sentiment: MediWound recently beat the consensus EPS estimate in its latest quarterly results, which may still provide some support for the stock.
Neutral Sentiment: Analyst estimates remain deeply negative overall, with MediWound still expected to post losses in 2026 through 2028, limiting the immediate bullish case.
Negative Sentiment: Maxim Group cut estimates across several periods, including Q2 2026, Q3 2026, Q4 2026, Q1 2027, Q2 2027, Q3 2027, Q4 2027, FY2027, FY2028, and FY2029, reflecting a weaker outlook for earnings growth.
Negative Sentiment: Craig Hallum lowered its FY2027 estimate, while Maxim also reduced its Q1 2028 and Q4 2027 forecasts, adding to concerns about slower profitability improvement.

MediWound Company Profile

(Get Free Report)

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.